SunTrust Defends Biogen (BIIB); 'Buy on Weakness'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Biogen (BIIB) 6% Lower as Aducanumab Timeline Pushed Out
April 22, 2020 7:50 AM EDTBiogen (NASDAQ: BIIB) is down 6% in pre-open trading despite strong results as the company said it stated submitting modules for aducanumab BLA and expects the U.S. filing in the third quarter, which pushes out the launch timelines.
... MoreBiogen (BIIB) Tops Q1 EPS by $1.40
April 22, 2020 7:04 AM EDTBiogen (NASDAQ: BIIB) reported Q1 EPS of $9.14, $1.40 better than the analyst estimate of $7.74. Revenue for the quarter came in at $3.53 billion versus the consensus estimate of $3.41 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
... More